Luxcia Kugathasan

14PUBLICATIONS
54CO-AUTHORS
Molecular targetsEpigenetics (incl. genome methylation and epigenomics)Cardiology (incl. cardiovascular diseases)PharmacogenomicsMedical biochemistry - amino acids and metabolites
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Aug 12, 2026
Authors' Reply: Could Calcineurin Inhibitor-Driven Sodium-Chloride Cotransporter Activation Explain Blunted Natriuresis with Sodium-Glucose Cotransporter 2 Inhibition in Kidney Transplant Recipients?

|Jul 03, 2026
Relationship Between hsCRP, Glycaemic Control and Response to Sotagliflozin in Type 1 Diabetes: A Post Hoc Analysis of the inTandem3 Trial.

|Feb 26, 2026
Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

Luxcia Kugathasan, Massimo Nardone, Marcel H A Muskiet

|Feb 02, 2026
Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial.

Luxcia Kugathasan, Michael A Tsoukas, Massimo Nardone

|Dec 12, 2025
Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial.

Vikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn

|Dec 05, 2025
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Vikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn

Pageof 3

Frequent Collaborators

7 joint publications

Vikas Srinivasan Sridhar

6 joint publications

David Z I Cherney

5 joint publications

Leif Erik Lovblom

3 joint publications

Alessandro Doria